Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Target Raised at Barclays

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price increased by research analysts at Barclays from $271.00 to $275.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price objective would indicate a potential upside of 19.40% from the stock’s current price.

A number of other brokerages have also weighed in on JAZZ. Deutsche Bank Aktiengesellschaft increased their price objective on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price on the stock. Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a report on Tuesday. Canaccord Genuity Group set a $300.00 target price on Jazz Pharmaceuticals in a report on Wednesday, August 26th. Finally, Needham & Company LLC raised their price objective on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $292.70.

Jazz Pharmaceuticals Trading Up 7.4%

NASDAQ:JAZZ traded up $15.88 during midday trading on Tuesday, hitting $230.32. The stock had a trading volume of 215,950 shares, compared to its average volume of 927,309. Jazz Pharmaceuticals has a one year low of $128.80 and a one year high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average of $231.16 and a 200 day moving average of $216.50. The company has a market capitalization of $14.95 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 0.41 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) EPS for the quarter, beating the consensus estimate of ($4.05) by $0.17. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the firm posted $8.13 earnings per share. As a group, sell-side analysts forecast that Jazz Pharmaceuticals will post 10.87 EPS for the current year.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renee D. Gala sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total value of $472,800.00. Following the transaction, the chief executive officer directly owned 141,394 shares of the company’s stock, valued at $33,425,541.60. The trade was a 1.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 94,121 shares of company stock worth $23,337,922 over the last ninety days. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. USA Financial Formulas acquired a new position in shares of Jazz Pharmaceuticals during the first quarter worth about $25,000. Pension & Wealth Management Advisors Inc. purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth approximately $32,000. Ameritas Advisory Services LLC acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $47,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $61,000. Finally, Elevation Wealth Partners LLC lifted its stake in Jazz Pharmaceuticals by 156.4% in the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock worth $60,000 after acquiring an additional 158 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported third-quarter revenue of approximately $1.24 billion, up 10.4% year over year and above the roughly $1.21 billion analyst estimate. Adjusted loss of $3.88 per share was narrower than the consensus loss of $4.05. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 revenue outlook to approximately $4.8 billion-$4.9 billion, above the $4.7 billion-$4.73 billion consensus range. The increased forecast signals continued confidence in commercial execution. Jazz 2026 Revenue Guidance
• Positive Sentiment: Ziihera launched in first-line HER2-positive metastatic gastric and esophageal cancer, while management identified potential peak sales of $3 billion-$5 billion. Xywav revenue also grew 12%, with 425 net patient additions during the quarter. Ziihera Launch and Guidance
• Neutral Sentiment: Jazz completed its Actio acquisition, adding the ABS-1230 epilepsy candidate to its rare-neurology portfolio. The company will also present Phase 3 ACTION and Phase 2 brain-cancer research at the Society for Neuro-Oncology meeting, offering potential future catalysts but no immediate revenue impact. Jazz Neuro-Oncology Research
• Negative Sentiment: The quarter’s loss contrasts sharply with $8.13 per-share earnings a year earlier. Investors may also remain cautious about decelerating growth and acquisition-related charges associated with Actio, leaving the stock at a crossroads despite the improved outlook. Jazz Earnings and Guidance Analysis

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.